Literature DB >> 25163534

The characterization and antibiotic resistance profiles of clinical Escherichia coli O25b-B2-ST131 isolates in Kuwait.

Ali A Dashti, Leila Vali1, Sherief El-Shazly, Mehrez M Jadaon.   

Abstract

BACKGROUND: Escherichia coli O25b-B2-ST131 are considered virulent extra-intestinal pathogens causing serious clinical complications such as urinary tract infection and bacteraemia. Our main objectives in this study were to characterise the multi-drug resistant (MDR) isolates of this lineage in Kuwait, and to demonstrate whether reduced susceptibility is spread clonally.
RESULTS: A subset of 83 (10%) non-duplicate and non-selective E. coli O25b-B2-ST131 out of 832 MDR E. coli was identified and collected. Minimum inhibitory concentrations of the isolates were determined and pulsed-field gel electrophoresis was used for typing.The majority (95.2%) of the 83 E. coli O25b-B2-ST131 harboured at least one bla gene with blaCTX-M-15 being the most prevalent. blaCTX-M-2 was present in one isolate. Also one isolate harboured blaCTX-M-56, qnrB1 and blaCMY-2 genes and carried IncF1 plasmids of about 97 kb and160 kb. qnrB and qnrS were found in 8 other blaCTX-M-15 containing isolates. The blaNDM, blaIMP, blaVIM and qnrA were not detected, however, the blaOXA-48 was present in two (2.4%).
CONCLUSIONS: The majority of isolates harbouring qnr genes demonstrated relatedness (≥85%) by PFGE. However, the diversity in PFGE profiles for the other MDR isolates reflected the changes in population genetics of E. coli O25b-B2-ST131. We identified for the first time the appearance of blaCTX-M-2 in the Middle East and blaCTX-M-56 outside the Latin American countries. The isolate harbouring blaCTX-M-56 also contained qnrB1 and blaCMY-2 genes and carried IncF1 plasmids. The appearance of a highly virulent E. coli O25b-ST131 that is resistant to penicillins, most cephalosproins, β-lactamase inhibitors as well as fluoroquinolones is a cause for concern.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25163534      PMCID: PMC4159528          DOI: 10.1186/s12866-014-0214-6

Source DB:  PubMed          Journal:  BMC Microbiol        ISSN: 1471-2180            Impact factor:   3.605


Background

Escherichia coli belonging to the phylogenic group B2, serotype O25b:H4 and Multi-Locus Sequence Type (ST) 131 (E. coli O25b-B2-ST131), producing extended-spectrum β-lactamase (ESBL) is regarded as a major pandemic clone in community and hospitals causing serious clinical infections such as urinary tract infections and bacteraemia [1]. It has been shown that E. coli O25b-B2-ST131 exhibits a high virulence score compared to other lineages [2] and is capable of acquiring antibiotic resistance by different mechanisms [3-6]. The fact that E. coli O25b-B2-ST131 is able to exhibit antibiotic resistance means that the clinical environment within a hospital or community may actively select certain resistant strains [7] making the treatment of these infections increasingly difficult. Analysis by pulsed field gel electrophoresis (PFGE) has identified a high degree of genetic diversity among the E. coli O25b-B2-ST131 isolates; however, some types appear to be more common in certain regions than others [4]. An important cause of resistance in E. coli O25b-B2-ST131 is the production of β-lactamase enzymes. Some of the most prevalent of these are CTX-M-like enzymes as well as other types specifically TEM-1, TEM-24, SHV-12 and the plasmid-mediated AmpC CMY-2 [8-10]. Furthermore, CTX-M-15 producing strains often co-produce both OXA-1 as well as variants of an aminoglycoside-modifying enzyme that is responsible for reduced susceptibility both to the aminoglycosides and to some fluoroquinolones expressed by aac(6’)-Ib-cr genes [5,6]. Fluoroquinolone (FQ) resistance in Enterobacteriaceae is usually caused by mutations in the chromosomal genes coding for type II topoisomerases and changes in the expression of efflux pumps and porins. The rise of plasmid-mediated FQ resistance protein Qnr [11] has caused concern in antimicrobial treatment of Enterobacteriaceae whereby carbapenems are considered the best therapeutic option [12]. Nevertheless some Enterobactericeae can produce clinically important carbapenemases; the Ambler class B metallo-β-lactamases (NDM, IMP, VIM), the class A enzymes (KPC) and the class D oxacillinase enzymes (OXA-48). Until recently E. coli was less often affiliated with carbapenemases than Klebsiella pneumoniae, however, the recent emergence of blaNDM gene (New Delhi metallo-β-lactamase) on plasmids in E.coli ST131strains has caused concern [13-15]. The NDM-like enzymes have been identified in different regions [16] including in clinical K. pneumoniae isolates from Kuwait [17] and Oman [18] in the Middle East. The blaOXA-48 carbapenemase is mainly associated with the Tn1999-like transposon inserted into a single 62-kb IncL/M-type plasmid [19]. It has been detected in sporadic cases; E. coli ST1196 (also containing resistance genes: blaCMY-2, blaSHV-12 and blaTEM-1) and E. coli ST1431 (containing β-lactamase genes: blaCTX-M-1, blaOXA-2 and blaTEM-1) isolated from pet dogs [20] and E. coli (containing blaCTX-M-15 and blaTEM-1 genes) isolated from a Belgian patient with ventilator-associated pneumonia travelling back from Egypt [21]. To date reports from the Middle East has been focused on the sporadic and selective E. coli O25b-B2-ST131 cases [22] and a comprehensive study on the epidemiology of this lineage was lacking. Therefore we aimed to address this issue by systematically characterising the multi-drug resistant (MDR) isolates of E. coli O25b-B2-ST131 recovered from patients in order to use these findings as a source for future reference studies and surveillances.

Methods

Bacterial isolates

A survey of Extended Spectrum β-lactamase (ESBL)-producing Enterobacteriaceae was undertaken from January 2010 to December 2012. A subset of 832 MDR E. coli strains was collected from the microbiology laboratories of three major hospitals that serve the six governorates of Kuwait. All the three hospitals are tertiary health care providers with bed capacities of 300 for Ahmadi, 500 for Amiri and 600 for Yiaco-Adan. The average number of specimens processed each day varies from 500 to 700 which includes samples from out-patient and in-patient specialists units. 832 original isolates represent a subset of the isolates submitted to the clinical diagnostic laboratories of these centres. Each patient was included only once in this study. A database was created based on the patient’s records that contained information; such as age, sex, hospital, location of care on each site, type of specimen and date of sampling. Specimens were processed by clinical staff members of the diagnostic laboratories using standard protocols. Cultures were performed on blood agar, MacConkey, Cystine lactose electrolyte deficient agar (CLED) and incubated aerobically and anaerobically as required. All isolates were identified at the species level based on colony morphology, biochemical analysis and by using Vitek2 (Vitek AMS; bioMérieux Vitek Systems Inc., Hazelwood, MO, USA). The isolates were stored in 10% skim milk and at -70°C. To confirm the phylogenic grouping of E. coli O25b-B2-ST131, PCR amplification of the pabB, trpA, chuA, yjaA genes [23] and DNA fragment of TSPE4.C2 were carried out as described before [24]. The products were sequenced from both directions and analysed.

Antimicrobial susceptibility testing

Antimicrobial susceptibility testing was determined by automated broth microdilution method (Vitek2) (Vitek AMS; BioMérieux Vitek Systems Inc., Durham, NC, USA) and the results were analysed according to the Clinical and Laboratory Standards Institute, CLSI (2012) guidelines [25]. The antibiotics tested in this study were: Amikacin, amoxicillin/clavulanic acid, amp/sulbactam, ampicillin, cefazolin, cefepime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, cefoxitin, cefpodoxime, cephalothin, ceftriazone, ciprofloxacin, gentamicin, imipenem, meropenem, levofloxacin, nitrofurantoin, norfloxacin, tetracycline, tobramycin, trimethoprim/sulfamethoxazole, piperacillin/tazobactam, pipercillin and tigecycline. ESBL production was confirmed by vitek2 analyzer and disk diffusion. Minimum inhibitory concentration (MICs) of quinolones, fluoro-quinolones and β-lactams including carbapenems were determined using the E-test method (CLSI 2012) [25]. Isolates that showed resistance to at least three classes of antibiotics were considered as MDR. Isolates that were detected as resistant to cefoxitin were further investigated for the presence of an ampC β-lactamase by using multiplex PCR [8,26].

Double-disc synergy method

ESBLs were detected as previously described [27] using the disc approximation and double-disc synergy methods and confirmed with cefotaxime and ceftazidime E-test ESBL strips (AB Biodisk, Biomerieux-diagnostics, Durham, NC, USA). For the disc approximation test, clavulanate diffusion from an amoxicillin–clavulanate (AMC30) disc was used to test for synergy with cefotaxime, ceftazidime, cefuroxime, cefepime and cefixime (Oxoid) as described previously [28]. For the double-disc synergy test, a ceftazidime disc (30 μg) was placed 30 mm away from a disc containing amoxicillin–clavulanate (60/10 μg). ESBL production was considered positive when an enhanced zone of inhibition was visible between the β-lactam and β-lactamase inhibitor-containing discs. For the E-test, ESBL strips containing ceftazidime and ceftazidimeclavulanate and strips containing cefotaxime and cefotaximeclavulanate were used to determine the MIC ratio according to the manufacturer’s instructions (AB Biodisk, Biomerieux-diagnostics, Durham, NC, USA). Cultures were incubated aerobically at 37°C for 18–24 h. CTX-M-15 β-lactamase enzyme displays a catalytic activity toward ceftazidime.

Modified Hodge test

The test inoculum (0.5 McFarland turbidity) was spread onto Mueller-Hinton agar plates and disks containing 30 μg ceftazidime (with and without 10 μg clavulanic acid) and 10 μg imipenem (with and without 750 μg EDTA) were placed on the surface of the media. The plates were incubated at 37°C overnight. P. aeruginosa NCTC 10662, E. coli NCTC 10418, and S. aureus NCTC 6571 were used as controls on every plate.

Identification of resistance genes

The presence of resistant genes listed below was investigated by PCR assays. PCR was conducted in a GeneAmp 9700 (Perkin-Elmer, Waltham Massachusetts, USA) system using the conditions specified for each primer; corresponding to the source references. blaTEM-1& blaSHV, blaCTX-M-like [9], blaNDM [13], blaOXA-1 [3], qnrA and qnrS [29], qnrB [30], aac(6’)-Ib Ib-cr [31], gyrA & parC [32], gyrB & parE [33]; intI1 [34] & intI2 [35], blaVIM, blaIMP, blaOXA-48 [19], ampC [8], IS [36]. Amplified PCR products were purified with Qiagen purification kit (Qiagen Valencia, CA, USA) according to the manufacturer’s instructions and both strands were sequenced by automated AB13100 DNA sequencer (Applied Biosystems, Carlsbad, CA, USA) system. The BLAST program of the National Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov) was used to search and compare databases for similar nucleotide acid sequences.

Pulsed-field gel electrophoresis

Pulsed-Field Gel Electrophoresis (PFGE) analysis was based on techniques described elsewhere [37]. After PFGE, the gels were stained with ethidium bromide and scanned. The analysis of the gels was performed using BioNumerics software version 7.1 (Applied Maths, Ghent, Belgium). This software facilitates the development of the algorithms necessary for the comparison of profiles of isolates based on the Dice coefficient and the hierarchic unweighted pair arithmetic average algorithm. Cluster analysis and phylogenetic trees were subsequently analysed with an optimization of 1.0% and a tolerance of 0.7%. Isolates were considered to belong to the same PFGE clone if their Dice similarity index was ≥85%.

Plasmid analysis

Plasmids were extracted (Promega, Fitchburg, WI, USA) and characterized by PCR as described previously [38]. Plasmids from clinical isolates were detected using PFGE. A single block was incubated at 55°C for 1 hour with 1 unit of S1 nuclease (New England Biolabs, Ipswich, MA, USA) in Zinc Buffer (200 μl of 50 mM NaCl, 30 mM sodium acetate and 5 mM ZnSO4). Electrophoresis was performed at 6 V, 5-50s for 20 h [39].

Resistance transfer assays

Mating experiments were performed with E. coli J62-2(RifR) as the recipient strain. Cultures of the donor (KOC-10 harbouring blaCTX-M-56,qnrB1 and blaCMY-2 genes) and the recipient strain were grown in Luria-Berani (LB) broth (109 cfu/ml) and mixed in the ratio of 1:4 and incubated for 5 hours at 37°C. Transconjugates (0.1 ml) were selected on LB agar plates containing rifampicin (150 mg/L) and cefotaxime (2 mg/L). The transconjugates were tested for antibiotic resistance followed by PCR of the resistance determinants.

Result

Bacterial isolates and the detection of O25b-ST131

All three hospitals participated during our study period; however there were inconsistencies in the level of strain contribution for each year. Therefore under-representation of E. coli multi-drug resistant isolates might exist. We tested a subset of 832 E. coli MDR (Table 1). Of which 83 (10%) were identified as the O25b-sequence type (ST) 131 clone of B2 phylogenic group. The principal source of isolation (81%) was urine; mainly from patients older than 60 years of age, these comprised 49% of all the urine specimens. The distribution of these 83 isolates and the source of isolation are presented in Table 2. (Also see Additional file 1).
Table 1

The distribution of 832 isolates by hospital, year, and sample from which the isolates were originally recovered

Hospital Total Year Urine Blood Wound Gastric Fluid Catheter tip Ascetic Fluid Eye Pleural Fluid Sputum Tissue Pus
Amiri (ADA) 2402010
201149122111
201217751
Ahmadi (KOC) 2362010877132873
20114811
2012512123
Yiaco-Adan (Y) 3562010
2011
2012305132412128
Table 2

The distribution of 83 isolates by hospital, year, and sample from which the isolates were originally recovered

Hospital Total no. Year Urine Blood Wound Pus Catheter tip Ascetic Fluid Eye Pleural Fluid Sputum
Amiri (ADA)92010
20111
20128
Ahamdi (KOC)5720103852221
20113
201231
Yiaco-Adan (Y)172010
2011
201213211
The distribution of 832 isolates by hospital, year, and sample from which the isolates were originally recovered The distribution of 83 isolates by hospital, year, and sample from which the isolates were originally recovered

PCR amplification and sequencing

Table 3 shows the distribution of the bla genes among the 83 isolates of E. coli O25b-ST131. Four (4.8%) did not contain any of the β-lactamase enzymes while the majority (95.2%) harboured at least one β-lactamase resistance gene. Two isolates harboured blaCTX-M-2 and blaCTX-M-56. blaNDM, blaIMP and blaVIM genes were not found. ISEcp1 was detected upstream region of 25 (33%) of the blaCTX-M-15 positive isolates. blaCMY-2 was only detected in four isolates (4.8%). IS elements were detected in 2 blaCMY-2 positive isolates, 1 contained class 1 integrons and 1 class II integrons.
Table 3

Molecular characterization of genes among O25b-B2-ST131in Kuwait

Profiles of the antibiotic resistance genes No. of isolates (%)
bla TEM-1 2 (2.4)
bla SHV-12 1 (1.2)
bla CTX-M-2 1 (1.2)
bla CTX-M-15 32 (38.6)
bla CTX-M-56 1 (1.2)
bla TEM-1, bla SHV-12 1 (1.2)
bla CTX-M-15, bla SHV-12 9 (10.8)
bla CTX-M-15, bla TEM-1 21 (25.3)
bla CTX-M-15, bla TEM-1, bla SHV-12 12 (14.5)
Molecular characterization of genes among O25b-B2-ST131in Kuwait Class 1 integrons were identified in 30 (36.1%) isolates and only 5 (6%) contained class II integrons. None of the isolates contained both classes of integrons.

Quinolone resistance determinants

All but two isolates were resistant or had intermediate resistance to ciprofloxacin (MIC > 2 mg/l). Two sensitive isolates did not contain aac(6’)-Ib Ib-cr (isolates Y-116 and Y-159). We did not detect qnrA gene in any of the isolates tested. Three isolates harboured qnrB1 and 4 harboured qnrS1. qnrB1 and qnrS1 coexisted in only 2 isolates (Table 4).
Table 4

The profile of quinolone resistant O25b-B2-ST131isolates

Profiles of the antibiotic resistance genes No. of Isolates
bla CTX-M-56, bla cmy-2, qnrB1 1
bla CTX-M-15, aac(6)-Ib-cr, bla TEM-1, qnrB1 1
bla CTX-M-15, aac(6)-Ib-cr, bla OXA-1, bla TEM-1, qnrB1, ISEcp1 1
bla CTX-M-15, aac(6)-Ib-cr, bla OXA-1,, bla TEM-1, qnrS1, ISEcp1 1
bla CTX-M-15, aac(6)-Ib-cr, bla OXA-1,, qnrB1, qnrS1 2
bla CTX-M-15, aac(6)-Ib-cr, bla OXA-1,, qnrS1, ISEcp1 2
bla CTX-M-15, qnrS1, bla OXA-1,, ISEcp1 1
Total 9
The profile of quinolone resistant O25b-B2-ST131isolates Fifty six (67.5%) isolates carried aac(6’)-Ib Ib-cr. Among the aac(6’)-Ib Ib-cr negative strains (27/83) 32.5%, 1 isolate carried qnrB1 and blaCTX-M-56 (KOC-10) and 1 isolate carried qnrS1 (ADA-234). The remaining 78% (7/9) qnr positive isolates also contained aac(6’)-Ib Ib-cr (Figure 1). None of the qnr positive isolates carried blaSHV.
Figure 1

PFGE profiles of O25b-B2-ST131isolates collected in this study harbouring genes. The degree of similarity is shown on the scale at the top left of the figure. Isolate no. Specimen Age Gender.

PFGE profiles of O25b-B2-ST131isolates collected in this study harbouring genes. The degree of similarity is shown on the scale at the top left of the figure. Isolate no. Specimen Age Gender. No mutations were detected in the quinolone-resistance-determining regions of gyrA. However, there was a new mutation in isolate D-140 topoisomerase subunit IV at position 520 G to C that altered 174 Val (GTC) to Leu (CTC) possibly not leading to any additional chromosome encoded fluoroquinolone resistance. We also observed mutations in isolate Y-190 in topoisomerase subunit IV; the amino acid 560A → V and at position 840 V → A.

PFGE

PFGE showed diverse genetic profiles (Figure 2). The isolates that harboured qnr genes; although resemble similar phenotypes; some displayed unrelated PFGE profiles suggesting that they were not epidemic cases (Figure 1). The genotyping results of the 5 isolates that contained class II integrons suggested that only two of these isolates have identical PF patterns and harboured similar antibiotic resistant profiles whereas the other three isolates were not closely related and contained different resistance genes including one isolate which contained the AmpC gene blaCMY-2. All 5 harboured blaCTX-M-15 (Figure 3).
Figure 2

Relationship between banding patterns after digestion with I endonuclease enzyme showing the percentage similarity between group types and clusters for 83 O25b-B2-ST131 isolates using DICE/UPGMA with an optimization of 1.0% and a tolerance of 0.5% generated by BioNumerics software (v.7.1).

Figure 3

PFGE profiles of O25b-B2-ST131isolates containing Class II integron.

Relationship between banding patterns after digestion with I endonuclease enzyme showing the percentage similarity between group types and clusters for 83 O25b-B2-ST131 isolates using DICE/UPGMA with an optimization of 1.0% and a tolerance of 0.5% generated by BioNumerics software (v.7.1). PFGE profiles of O25b-B2-ST131isolates containing Class II integron.

Antimicrobial susceptibility

We identified 3 (3.6%) of the E. coli O131 isolates did not contain β-lactam resistance genes which reflect the infection caused by cephalosporin-susceptible clones (KOC-3, KOC-47 and Y-136). These isolates were collected from two different hospitals, all from urine specimens and were not related by PFGE to each other but were closely related to other isolates that contained blaCTX-M-15 (Figure 2). IncFII plasmid that also contains β-lactamase gene blaOXA-1 that encodes for OXA-1 and the aminoglycoside/fluoroquinolone acetyl transferase aac(6’)-Ib-cr was present in 58 (70%) of isolates of which 33 (40%) contained both genes. The isolate (KOC10) harbouring blaCTX-M-56 gene also contained qnrB1 and bla genes and carried IncF1 plasmids of about 97 kb and 160 kb (Figure 4). Number of transconjugants in 1 ml for KOC10 was on average 40 to 6 × 102 which comprised of 4 × 10−8 to 6 × 10−7 transconjugants per donor cell. PCR revealed that only one of the transconjugates contained qnrB1 and blaCMY-2 genes and one contained qnrB1 and blaCTX-M-56.
Figure 4

Agarose gel showing S1 nuclease PFGE-based sizing of large plasmids from O25b-B2-ST131 harbouring .

Agarose gel showing S1 nuclease PFGE-based sizing of large plasmids from O25b-B2-ST131 harbouring .

Discussion

This manuscript reports the trend of E. coli O25b-ST131 isolated non-selectively in hospitals. During our two year study 10% of MDR E. coli isolated belonged to the E. coli O25b-ST131 clonal group indicating that the Middle East has joined the countries affected by this virulent pathogen posing a major public health concern. MDR E. coli O25b-ST131isolates were isolated from different age groups of patients (3-94 years old; with the average age of 54.4 years old). The majority of isolates (38.6%) harboured only blaCTX-M-15 and 10.8% also contained blaTEM and or blaSHV. Among ESBL producers; we detected the presence of blaCTX-M-56 for the first time in the Middle East and outside the South American continent [40]. The patient from which the isolate was recovered had an international travel history to an endemic region. Also we detected blaCTX-M-2, one of the dominant Asian β-lactamases [41] for the first time in the Middle East. blaCTX-M-56 gene is in the same context as blaCTX-M-2 by a single nucleotide mutation (G824A), resulting in a replacement of serine by asparagine at position 275 [42]. Previously no explanation was given as to what this change means, however we propose that based on other class A β-lactamases [43,44], as this modification takes place at the C terminal of the α-11 helix it is involved in the resistance to inactivation by β-lactamase inhibitors. The isolate harbouring blaCTX-M-56 also contained qnrB1 and blaCMY-2 genes and carried IncF1 plasmids of about 97 kb and160 kb. Production of plasmid AmpC such as cmy genes confers resistance to all penicillins, most cephalosporins and currently available β-lactamase inhibitors. Therefore the emergence of a clinical isolate that contains blaCMY-2 as well as blaCTX-M-56 poses a risk to combination β-lactam/ β-lactamase inhibitor therapy. We also detected the presence of qnr genes in eight other blaCTX-M-15 harbouring isolates. Although Qnr enzyme by itself produces low-level resistance to quinolones, its presence facilitates the selection of higher-level resistance, thus contributing to the alarming increase in resistance to quinolones. ISEcp1-blaCTX-M-15 element was located in the upstream region of 33% of isolates harbouring blaCTX-M-15. Twenty seven per cent of which were associated with blaSHV,blaTEM as well as blaCTX-M-15. ISEcp1 plays a role in gene transfer or in providing a promoter for β-lactamase genes and supports their dissemination [45]. IncFII plasmid that also harboured blaOXA-1 and the aminoglycoside/fluoroquinolone acetyl transferase aac(6’)-Ib-cr gene (aac(6’)-Ib Ib-cr) was present in 59 (71%) of isolates of which 33 (40%) contained both genes. Two isolates containing blaOXA-48 contained ISEcp1 and class 1 integrons. It has been reported [46] that a novel Tn1999 transposon inserted into a single 62-kb IncL/M-type plasmid is responsible for the dissemination of blaOXA-48 gene in E. coli strains. The rate of carriage of MDR E. coli O25b-ST131 is estimated at 7% in healthy adults [47]; however the rate of E. coli O25b-ST131 susceptible to extended-spectrum cephalosporins has never been reported. We identified 3.6% of the E. coli O131 isolates did not contain any of the related resistance genes which reflect the infection caused by cephalosporin-susceptible clones.

Conclusion

We did not find any association between resistance profiles and genotypes. However; we detected for the first time the appearance blaCTX-M-2 in the Middle East and blaCTX-M-56 outside Latin America. We also identified the spread of qnrB1 and qnrS1 in isolates harbouring aac(6’)-Ib Ib-cr and blaCTX-M. The isolate harbouring blaCTX-M-56 also contained qnrB1 and blaCMY-2 genes and carried IncF1 plasmids. In conclusion the appearance of a highly virulent E. coli O25b-ST131 that is resistant to penicillins, most cephalosproins, β-lactamase inhibitors as well as floroquinolones is a cause for concern and poses a risk to combination β-lactam/ β-lactamase inhibitor therapy.
  46 in total

Review 1.  Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.

Authors:  E B Chaïbi; D Sirot; G Paul; R Labia
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

2.  Pentapeptide repeat proteins.

Authors:  Matthew W Vetting; Subray S Hegde; J Eduardo Fajardo; Andras Fiser; Steven L Roderick; Howard E Takiff; John S Blanchard
Journal:  Biochemistry       Date:  2006-01-10       Impact factor: 3.162

3.  Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme.

Authors:  Chi Hye Park; Ari Robicsek; George A Jacoby; Daniel Sahm; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

4.  Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom.

Authors:  E Karisik; M J Ellington; R Pike; R E Warren; D M Livermore; N Woodford
Journal:  J Antimicrob Chemother       Date:  2006-07-26       Impact factor: 5.790

5.  Identification of plasmids by PCR-based replicon typing.

Authors:  Alessandra Carattoli; Alessia Bertini; Laura Villa; Vincenzo Falbo; Katie L Hopkins; E John Threlfall
Journal:  J Microbiol Methods       Date:  2005-06-02       Impact factor: 2.363

6.  Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet.

Authors:  Efrain M Ribot; M A Fair; R Gautom; D N Cameron; S B Hunter; B Swaminathan; Timothy J Barrett
Journal:  Foodborne Pathog Dis       Date:  2006       Impact factor: 3.171

7.  Prevalence of qnr genes in Salmonella in France.

Authors:  Vincent Cattoir; François-Xavier Weill; Laurent Poirel; Laëtitia Fabre; Claude-James Soussy; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2007-02-16       Impact factor: 5.790

8.  Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field.

Authors:  E Giraud; A Brisabois; J L Martel; E Chaslus-Dancla
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

9.  CTX-M-15-producing multidrug-resistant enteroaggregative Escherichia coli in the United Arab Emirates.

Authors:  A Sonnevend; K Al Dhaheri; T Mag; M Herpay; J Kolodziejek; N Nowotny; A Usmani; F A Sheikh; T Pál
Journal:  Clin Microbiol Infect       Date:  2006-06       Impact factor: 8.067

Review 10.  Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae.

Authors:  Patrice Nordmann; Laurent Poirel
Journal:  J Antimicrob Chemother       Date:  2005-07-14       Impact factor: 5.790

View more
  8 in total

1.  Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii.

Authors:  Sherief El-Shazly; Ali Dashti; Leila Vali; Michael Bolaris; Ashraf S Ibrahim
Journal:  Int J Infect Dis       Date:  2015-10-27       Impact factor: 3.623

2.  Convergence of plasmid architectures drives emergence of multi-drug resistance in a clonally diverse Escherichia coli population from a veterinary clinical care setting.

Authors:  Sam Wagner; Nadejda Lupolova; David L Gally; Sally A Argyle
Journal:  Vet Microbiol       Date:  2017-09-22       Impact factor: 3.293

3.  The emergence of plasmid mediated quinolone resistance qnrA2 in extended spectrum β-lactamase producing Klebsiella pneumoniae in the Middle East.

Authors:  Leila Vali; Ali A Dashti; Mehrez M Jadaon; Sherief El-Shazly
Journal:  Daru       Date:  2015-06-28       Impact factor: 3.117

Review 4.  Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis.

Authors:  M J D Dautzenberg; M R Haverkate; M J M Bonten; M C J Bootsma
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

5.  Antibiotic-Resistance Genes in E. coli strains in GCC Countries: A Meta-Analysis.

Authors:  Khalid Mubarak Bindayna; Ronni Mol Joji; Hicham Ezzat; Haitham Ali Jahrami
Journal:  Saudi J Med Med Sci       Date:  2022-01-17

Review 6.  Emerging Status of Multidrug-Resistant Bacteria and Fungi in the Arabian Peninsula.

Authors:  J Francis Borgio; Alia Saeed Rasdan; Bayan Sonbol; Galyah Alhamid; Noor B Almandil; Sayed AbdulAzeez
Journal:  Biology (Basel)       Date:  2021-11-06

7.  Molecular epidemiology of cefotaxime-resistant but ceftazidime-susceptible Enterobacterales and evaluation of the in vitro bactericidal activity of ceftazidime and cefepime.

Authors:  Martín L Marchisio; Karen I Liebrenz; Emilce de Los A Méndez; José A Di Conza
Journal:  Braz J Microbiol       Date:  2021-07-16       Impact factor: 2.214

Review 8.  Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.

Authors:  Iman Dandachi; Amer Chaddad; Jason Hanna; Jessika Matta; Ziad Daoud
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.